Single-center experience of surgically resected gastrointestinal stromal tumors: A report of six cases, including a rare case involving the lower esophagus

被引:6
作者
Al-Jiffry, Bilal O. [1 ,2 ]
Allam, Hisham M. [2 ]
Hatem, Mohammed [1 ]
机构
[1] Taif Univ, Dept Surg, At Taif 21944, Saudi Arabia
[2] Al Hada Mil Hosp, Dept Surg, At Taif 21944, Saudi Arabia
关键词
gastrointestinal stromal tumors; esophagus; imatinib; DIAGNOSIS; MANAGEMENT;
D O I
10.3892/ol.2014.2792
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumors (GISTs) are rare, but remain the most common GI mesenchymal neoplasms. In the present study, six cases of GIST are reported, and one of these cases, a patient with esophageal GIST, is reported in-depth. Certain recent developments in the clinical therapy of GISTs are also discussed. The records of all surgically-resected GI stromal tumors treated at the Al-Hada Military Hospital between January 2007 and December 2012 were reviewed. There were six cases of surgically resected GISTs during this time period, three males and three females, with a mean age of 69.3 16.4 years. The stomach was involved in 66.7% of cases, the small intestine in 16.7% and the esophagus, which is an extremely rare site, in 16.7% of cases. The most common symptom at presentation was abdominal pain, followed by GI bleeding. The mean tumor size was 8.7 +/- 6.3 cm. Surgery was indicated by the presence of the aforementioned symptoms or a tumor size >5 cm. All tumors were completely resected with histologically negative margins. The diagnoses were established by immunohistochemistry. Four patients were classified as possessing a high-grade variant, and were administered with tyrosine kinase inhibitors (TKIs). Following a mean follow up of 31 months, no recurrence or mortality was detected. Complete surgical resection with tumor-free margins is the standard treatment for GISTs, and TKIs should be used as adjuvant therapy if the risk of progressive disease is high.
引用
收藏
页码:745 / 748
页数:4
相关论文
共 15 条
[1]   Gastrointestinal stromal tumours:: Consensus statement on diagnosis and treatment [J].
Blackstein, ME ;
Blay, JY ;
Corless, C ;
Driman, DK ;
Riddell, R ;
Soulières, D ;
Swallow, CJ ;
Verma, S .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 20 (03) :157-163
[2]   Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors [J].
Blum, Matthew G. ;
Bilimoria, Karl Y. ;
Wayne, Jeffrey D. ;
de Hoyos, Alberto L. ;
Talamonti, Mark S. ;
Adley, Brian .
ANNALS OF THORACIC SURGERY, 2007, 84 (05) :1717-1723
[3]   Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].
Casali, P. G. ;
Jost, L. ;
Reichardt, P. ;
Schlemmer, M. ;
Blay, J. -Y. .
ANNALS OF ONCOLOGY, 2008, 19 :35-38
[4]   Molecular pathobiology of gastrointestinal stromal sarcomas [J].
Corless, Christopher L. ;
Heinrich, Michael C. .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2008, 3 :557-586
[5]   Two hundred gastrointestinal stromal tumors - Recurrence patterns and prognostic factors for survival [J].
DeMatteo, RP ;
Lewis, JJ ;
Leung, D ;
Mudan, SS ;
Woodruff, JM ;
Brennan, MF .
ANNALS OF SURGERY, 2000, 231 (01) :51-58
[6]  
Demetri GD, 2011, CANC PRINCIPLES PRAC, P1060
[7]  
Edge SB., 2010, AJCC Cancer Staging Manual, V7th, P175
[8]   Outcome of metastatic GIST in the era before tyrosine kinase inhibitors [J].
Gold, Jason S. ;
van der Zwan, Sanne M. ;
Goenen, Mithat ;
Maki, Robert G. ;
Singer, Samuel ;
Brennan, Murray F. ;
Antonescu, Cristina R. ;
De Matteo, Ronald P. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (01) :134-142
[9]   Management of malignant gastrointestinal stromal tumours [J].
Joensuu, H ;
Fletcher, C ;
Dimitrijevic, S ;
Silberman, S ;
Roberts, P ;
Demetri, G .
LANCET ONCOLOGY, 2002, 3 (11) :655-664
[10]   Gastrointestinal stromal tumour [J].
Joensuu, Heikki ;
Hohenberger, Peter ;
Corless, Christopher L. .
LANCET, 2013, 382 (9896) :973-983